IP Library Granted Patent US 8,129,405
Granted Patent B2
US 8,129,405 · App. 13/011,131 · Granted Mar 6, 2012

Quinuclidine derivatives and medicinal compositions containing the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,129,405
App. No.
13/011,131
Granted
Mar 6, 2012
Kind
B2
Abstract

The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in powder inhalant form, and methods of using it for treatment of respiratory disorders.

Claims (15)

1. A pharmaceutical composition comprising:

(i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X − with a single negative charge is associated with the positive charge of the nitrogen atom; and

(ii) a β 2 agonist.

2. The composition of claim 1 further comprising a pharmaceutically acceptable carrier or diluent.

3. The composition of claim 1 wherein the anion X 31 is chloride, bromide, iodide, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p-toluenesulfonate, or trifluoroacetate.

4. The composition of claim 1 which is suitable for inhalation.

5. The composition of claim 1 wherein the composition is a liquid inhalant, powder inhalant, or inhalation aerosol.

6. The composition of claim 1 further comprising a steroid.

7. The composition of claim 6 further comprising a phosphodiesterase IV inhibitor.

8. The composition of claim 1 further comprising a phosphodiesterase IV inhibitor.

9. The composition of claim 2 wherein the pharmaceutically acceptable carrier or diluent is lactose.

10. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of the composition of claim 1 .

11. The method of claim 10 further comprising administering an effective amount of a steroid.

12. The method of claim 11 further comprising administering an effective amount of phosphodiesterase IV inhibitor.

13. The method of claim 10 further comprising administering an effective amount of phosphodiesterase IV inhibitor.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: FERNANDEZ FORNER, MARIA DOLORS; PRAT QUINONES, MARIA; BUIL ALBERO, MARIA ANTONIA
To: ALMIRALL PRODESFARMA, S.A.
Reel/Frame 042416/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: ALMIRALL PRODESFARMA, S.A.
To: ALMIRALL PRODESFARMA AG
Reel/Frame 042416/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: ALMIRALL AG
To: LABORATORIOS ALMIRALL, S.A.
Reel/Frame 042417/0118 →
CHANGE OF NAME Recorded May 17, 2017
From: ALMIRALL PRODESFARMA AG
To: ALMIRALL AG
Reel/Frame 042490/0468 →
CHANGE OF NAME Recorded May 17, 2017
From: LABORATORIOS ALMIRALL, S.A.
To: ALMIRALL, S.A.
Reel/Frame 042490/0721 →